A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Assessment of adherence to mesalazine maintenance therapy over 1 year using memscaps monitoring system: a substudy of the coda trial comparing once- versus three times daily asacol in ulcerative colitis (UC)
2011
Gut
Introduction The Colitis Once Daily Asacol (CODA) study assed the effi cacy and safety of once daily dosing with Asacol 2.4 g (3 × 800 mg tablets) (OD) versus three times daily. Emerging evidence suggests OD mesalazine is as effective as divided doses. This has been attributed to better adherence, but detailed measures of adherence were lacking in previous studies. The Medication Event Monitoring System (MEMS) based in a bottle cap records the time each time the bottle is opened, giving
doi:10.1136/gut.2011.239301.312
fatcat:abt4sqaq5zh3nf7k5qvqjmpll4